Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.Adjusted EBITDA rose 12% to $206 million, while adjusted diluted earnings per share increased 20% to $0.30. ...

Glen Santangelo - Analyst None - Analyst David Amsellem - Analyst Ash Verma - Analyst Matt Dellatorre - Analyst Operator Amneal Pharmaceuticals (NasdaqGS:AMRX) Q2 2026 Earnings call July 30, 2026 08:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - Co-CEO and President Chintu Patel - Co-CEO Tasos Konidaris - EVP and CFO Conference Call Participants Good morning, and welcome to the Amneal Pharmaceuticals second quarter 2026 earnings call. I will now turn the call over to Am ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q2 2026 Earnings call July 30, 2026 08:30 AM ET Thank you. Good morning, everyone. Amneal is in the midst of the most transformative period in our company's history. We are growing as one of the America's leading affordable medicines businesses with an increasingly diversified and high-impact medicines portfolio, including Specialty brands, biosimilars, GLP-1s, and complex generics across dosage forms such as transdermals and injectables. As we execute our strategy, we ...